Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Multiple Sclerosis Therapeutics
1.2.3 Alzheimer's Disease Therapeutics
1.2.4 Parkinson's Disease Therapeutics
1.2.5 Parkinson's Disease Therapeutics
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Diseases Therapeutics Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Child
1.3.3 Aldult
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Diseases Therapeutics Market Perspective (2018-2033)
2.2 Neurodegenerative Diseases Therapeutics Growth Trends by Region
2.2.1 Global Neurodegenerative Diseases Therapeutics Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Neurodegenerative Diseases Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Neurodegenerative Diseases Therapeutics Forecasted Market Size by Region (2024-2033)
2.3 Neurodegenerative Diseases Therapeutics Market Dynamics
2.3.1 Neurodegenerative Diseases Therapeutics Industry Trends
2.3.2 Neurodegenerative Diseases Therapeutics Market Drivers
2.3.3 Neurodegenerative Diseases Therapeutics Market Challenges
2.3.4 Neurodegenerative Diseases Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue
3.1.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Neurodegenerative Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Diseases Therapeutics Revenue
3.4 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio
3.4.1 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Therapeutics Revenue in 2022
3.5 Neurodegenerative Diseases Therapeutics Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Diseases Therapeutics Product Solution and Service
3.7 Date of Enter into Neurodegenerative Diseases Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Diseases Therapeutics Breakdown Data by Type
4.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Type (2024-2033)
5 Neurodegenerative Diseases Therapeutics Breakdown Data by Application
5.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Neurodegenerative Diseases Therapeutics Market Size (2018-2033)
6.2 North America Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2018-2023)
6.4 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurodegenerative Diseases Therapeutics Market Size (2018-2033)
7.2 Europe Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2018-2023)
7.4 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size (2018-2033)
8.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurodegenerative Diseases Therapeutics Market Size (2018-2033)
9.2 Latin America Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size (2018-2033)
10.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AB Science SA
11.1.1 AB Science SA Company Detail
11.1.2 AB Science SA Business Overview
11.1.3 AB Science SA Neurodegenerative Diseases Therapeutics Introduction
11.1.4 AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023)
11.1.5 AB Science SA Recent Development
11.2 AbbVie Inc.
11.2.1 AbbVie Inc. Company Detail
11.2.2 AbbVie Inc. Business Overview
11.2.3 AbbVie Inc. Neurodegenerative Diseases Therapeutics Introduction
11.2.4 AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023)
11.2.5 AbbVie Inc. Recent Development
11.3 Acadia Pharmaceuticals Inc.
11.3.1 Acadia Pharmaceuticals Inc. Company Detail
11.3.2 Acadia Pharmaceuticals Inc. Business Overview
11.3.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Introduction
11.3.4 Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023)
11.3.5 Acadia Pharmaceuticals Inc. Recent Development
11.4 Biogen Inc.
11.4.1 Biogen Inc. Company Detail
11.4.2 Biogen Inc. Business Overview
11.4.3 Biogen Inc. Neurodegenerative Diseases Therapeutics Introduction
11.4.4 Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023)
11.4.5 Biogen Inc. Recent Development
11.5 F. Hoffmann La Roche Ltd.
11.5.1 F. Hoffmann La Roche Ltd. Company Detail
11.5.2 F. Hoffmann La Roche Ltd. Business Overview
11.5.3 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Introduction
11.5.4 F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023)
11.5.5 F. Hoffmann La Roche Ltd. Recent Development
11.6 H Lundbeck AS
11.6.1 H Lundbeck AS Company Detail
11.6.2 H Lundbeck AS Business Overview
11.6.3 H Lundbeck AS Neurodegenerative Diseases Therapeutics Introduction
11.6.4 H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023)
11.6.5 H Lundbeck AS Recent Development
11.7 Mitsubishi Chemical Holdings Corp.
11.7.1 Mitsubishi Chemical Holdings Corp. Company Detail
11.7.2 Mitsubishi Chemical Holdings Corp. Business Overview
11.7.3 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Introduction
11.7.4 Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023)
11.7.5 Mitsubishi Chemical Holdings Corp. Recent Development
11.8 Novartis AG
11.8.1 Novartis AG Company Detail
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Neurodegenerative Diseases Therapeutics Introduction
11.8.4 Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023)
11.8.5 Novartis AG Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Detail
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Neurodegenerative Diseases Therapeutics Introduction
11.9.4 Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023)
11.9.5 Sanofi Recent Development
11.10 Teva Pharmaceutical Industries Ltd
11.10.1 Teva Pharmaceutical Industries Ltd Company Detail
11.10.2 Teva Pharmaceutical Industries Ltd Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Introduction
11.10.4 Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023)
11.10.5 Teva Pharmaceutical Industries Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Multiple Sclerosis Therapeutics
Table 3. Key Players of Alzheimer's Disease Therapeutics
Table 4. Key Players of Parkinson's Disease Therapeutics
Table 5. Key Players of Parkinson's Disease Therapeutics
Table 6. Key Players of Others
Table 7. Global Neurodegenerative Diseases Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Neurodegenerative Diseases Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 9. Global Neurodegenerative Diseases Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Neurodegenerative Diseases Therapeutics Market Share by Region (2018-2023)
Table 11. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 12. Global Neurodegenerative Diseases Therapeutics Market Share by Region (2024-2033)
Table 13. Neurodegenerative Diseases Therapeutics Market Trends
Table 14. Neurodegenerative Diseases Therapeutics Market Drivers
Table 15. Neurodegenerative Diseases Therapeutics Market Challenges
Table 16. Neurodegenerative Diseases Therapeutics Market Restraints
Table 17. Global Neurodegenerative Diseases Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Neurodegenerative Diseases Therapeutics Market Share by Players (2018-2023)
Table 19. Global Top Neurodegenerative Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2022)
Table 20. Ranking of Global Top Neurodegenerative Diseases Therapeutics Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Neurodegenerative Diseases Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Neurodegenerative Diseases Therapeutics Product Solution and Service
Table 24. Date of Enter into Neurodegenerative Diseases Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurodegenerative Diseases Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type (2018-2023)
Table 28. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 29. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type (2024-2033)
Table 30. Global Neurodegenerative Diseases Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Application (2018-2023)
Table 32. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 33. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Application (2024-2033)
Table 34. North America Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. North America Neurodegenerative Diseases Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Neurodegenerative Diseases Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 37. Europe Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 38. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 40. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 41. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2024-2033) & (US$ Million)
Table 43. Latin America Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 46. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 47. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 49. AB Science SA Company Detail
Table 50. AB Science SA Business Overview
Table 51. AB Science SA Neurodegenerative Diseases Therapeutics Product
Table 52. AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023) & (US$ Million)
Table 53. AB Science SA Recent Development
Table 54. AbbVie Inc. Company Detail
Table 55. AbbVie Inc. Business Overview
Table 56. AbbVie Inc. Neurodegenerative Diseases Therapeutics Product
Table 57. AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023) & (US$ Million)
Table 58. AbbVie Inc. Recent Development
Table 59. Acadia Pharmaceuticals Inc. Company Detail
Table 60. Acadia Pharmaceuticals Inc. Business Overview
Table 61. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product
Table 62. Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023) & (US$ Million)
Table 63. Acadia Pharmaceuticals Inc. Recent Development
Table 64. Biogen Inc. Company Detail
Table 65. Biogen Inc. Business Overview
Table 66. Biogen Inc. Neurodegenerative Diseases Therapeutics Product
Table 67. Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023) & (US$ Million)
Table 68. Biogen Inc. Recent Development
Table 69. F. Hoffmann La Roche Ltd. Company Detail
Table 70. F. Hoffmann La Roche Ltd. Business Overview
Table 71. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product
Table 72. F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023) & (US$ Million)
Table 73. F. Hoffmann La Roche Ltd. Recent Development
Table 74. H Lundbeck AS Company Detail
Table 75. H Lundbeck AS Business Overview
Table 76. H Lundbeck AS Neurodegenerative Diseases Therapeutics Product
Table 77. H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023) & (US$ Million)
Table 78. H Lundbeck AS Recent Development
Table 79. Mitsubishi Chemical Holdings Corp. Company Detail
Table 80. Mitsubishi Chemical Holdings Corp. Business Overview
Table 81. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product
Table 82. Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023) & (US$ Million)
Table 83. Mitsubishi Chemical Holdings Corp. Recent Development
Table 84. Novartis AG Company Detail
Table 85. Novartis AG Business Overview
Table 86. Novartis AG Neurodegenerative Diseases Therapeutics Product
Table 87. Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023) & (US$ Million)
Table 88. Novartis AG Recent Development
Table 89. Sanofi Company Detail
Table 90. Sanofi Business Overview
Table 91. Sanofi Neurodegenerative Diseases Therapeutics Product
Table 92. Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023) & (US$ Million)
Table 93. Sanofi Recent Development
Table 94. Teva Pharmaceutical Industries Ltd Company Detail
Table 95. Teva Pharmaceutical Industries Ltd Business Overview
Table 96. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product
Table 97. Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2018-2023) & (US$ Million)
Table 98. Teva Pharmaceutical Industries Ltd Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Diseases Therapeutics Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Neurodegenerative Diseases Therapeutics Market Share by Type: 2022 VS 2033
Figure 3. Multiple Sclerosis Therapeutics Features
Figure 4. Alzheimer's Disease Therapeutics Features
Figure 5. Parkinson's Disease Therapeutics Features
Figure 6. Parkinson's Disease Therapeutics Features
Figure 7. Others Features
Figure 8. Global Neurodegenerative Diseases Therapeutics Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 9. Global Neurodegenerative Diseases Therapeutics Market Share by Application: 2022 VS 2033
Figure 10. Child Case Studies
Figure 11. Aldult Case Studies
Figure 12. Neurodegenerative Diseases Therapeutics Report Years Considered
Figure 13. Global Neurodegenerative Diseases Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 14. Global Neurodegenerative Diseases Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 15. Global Neurodegenerative Diseases Therapeutics Market Share by Region: 2022 VS 2033
Figure 16. Global Neurodegenerative Diseases Therapeutics Market Share by Players in 2022
Figure 17. Global Top Neurodegenerative Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Neurodegenerative Diseases Therapeutics Revenue in 2022
Figure 19. North America Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. North America Neurodegenerative Diseases Therapeutics Market Share by Country (2018-2033)
Figure 21. United States Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Canada Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Neurodegenerative Diseases Therapeutics Market Share by Country (2018-2033)
Figure 25. Germany Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. France Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. U.K. Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Italy Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Russia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Nordic Countries Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Share by Region (2018-2033)
Figure 33. China Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Japan Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. South Korea Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Southeast Asia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. India Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Australia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Neurodegenerative Diseases Therapeutics Market Share by Country (2018-2033)
Figure 41. Mexico Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Brazil Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Share by Country (2018-2033)
Figure 45. Turkey Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Saudi Arabia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. AB Science SA Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2018-2023)
Figure 48. AbbVie Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2018-2023)
Figure 49. Acadia Pharmaceuticals Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2018-2023)
Figure 50. Biogen Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2018-2023)
Figure 51. F. Hoffmann La Roche Ltd. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2018-2023)
Figure 52. H Lundbeck AS Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2018-2023)
Figure 53. Mitsubishi Chemical Holdings Corp. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2018-2023)
Figure 54. Novartis AG Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2018-2023)
Figure 55. Sanofi Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2018-2023)
Figure 56. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2018-2023)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed